PBI News & Analysis
3 articles
Market Mood
Pitney Bowes (PBI) CEO Sells $3.45M in Shares
Kurt Wolf, the president and CEO of Pitney Bowes (PBI), sold $3.45 million worth of shares of the company. This transaction could signal potential shifts in insider sentiment regarding the company's stock performance. Such sales by executives can influence market perception and investor decisions. Monitoring insider trading activity is essential for investors as it may reflect underlying confidence in the company's future prospects.
Read More: Pitney Bowes (PBI) CEO Sells $3.45M in Shares
Purple Biotech Price Target Cut by H.C. Wainwright
H.C. Wainwright has lowered its price target for Purple Biotech without specifying a new figure. This adjustment comes amid ongoing evaluations of the company’s preclinical progress. While the preclinical results were not detailed, this news reflects the progress of Purple Biotech's development pipeline. A reduction in target price could impact investor sentiment and trading decisions regarding Purple Biotech stock.
Read More: Purple Biotech Price Target Cut by H.C. Wainwright
Pitney Bowes (PBI) CEO Sells 200K Shares for $2.2 Million
Kurt James Wolf, President & CEO of Pitney Bowes (PBI), sold 200,208 common shares for approximately $2.22 million, as reported in an SEC Form 4 filing. This sale accounted for about 2.5% of his total holdings, which now stand at approximately 8,009,831 shares. The shares were sold at a weighted average price of $11.08, aligning with the April 2, 2026 market close of $11.03. For fiscal year 2023, Pitney Bowes reported revenue of $1.89 billion and a net income of $144.70 million.
Read More: Pitney Bowes (PBI) CEO Sells 200K Shares for $2.2 Million